Global sales of diet drug Acomplia (rimonabant), available in Europe but not approved in the U.S., are not even close to the sales being racked up by over-the-counter diet pill alli in the U.S. market, according to the two drugs' distributors.

"I am not pleased with the performance of Acomplia," Hanspeter Spek, Sanofi's excutive vice president for pharmaceutical operations, said in reporting total sales of the diet pill amounted to only $30 million in the third quarter of 2007.

That is far less than sales of alli (low-dose Xenical), which have totaled an estimated $150 million since the first FDA-approved non-prescription diet pill went on sale in the U.S. on June 15th.

Blaming the FDA, where an expert panel recommended against approval of rimonabant (called Zimulti in the U.S.) out of concern over side-effects, and the European Medicines Agency, which required that a letter of caution be sent to doctors, Spek termed Acomplia's performance "unpleasantly flat."

"Overall, we have to be clear and open with you that, within the current environment, the product will see only marginal progress and the next important step for this product is 2009," Spek told analysts.

But with an estimated 100,000 overweight and obese individuals now taking Acomplia, Spek said the good news is that safety reports do not show "any disturbing signal of an increase of evidence of side effects or any new kind of side effects."

It was concern over psychiatric side-effects of the drug -- including depression and increased incidences of suicidality -- that led to the FDA panel of independent experts recommending against approval of rimonabant in the U.S. Sanofi subsequently withdrew its application rather than waiting for FDA action.

But Spek reiterated again on Oct. 31 that Sanofi ultimately intends to resubmit its application in the United States -- and in the European Union and other nations as well -- based on current clinical trials that Sanofi believes will show rimonabant a valuable drug for treating type 2 diabetes as well as obesity.

"All our clinical trials go in the direction of diabetes," Spek said. He added that by 2009, Sanofi expects to have "a clearcut indication in diabetes where we have a new starting point with all the countries -- with all the institutions -- to get reimbursement" for use of the drug by overweight and diabetic patients.